The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

This publication has 9 references indexed in Scilit:

• The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapya combined analysis of two randomised, placebo-controlled phase III clinical trials
  European Journal Of Cancer, 2004
• The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
  Journal of Clinical Oncology, 2003
• 937 Superiority of aprepitant, an oral NK1 antagonist, over standard antiemetic therapy: Reducing the impact of nausea and vomiting on patients' daily lives
  European Journal of Cancer Supplements, 2003
• Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
  Clinical Pharmacology & Therapeutics, 2003
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
  Cancer, 2003
• Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
  European Journal Of Cancer, 2003
• Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
  Journal of Clinical Oncology, 1999
• Serotonin Mechanisms in Chemotherapy-Induced Emesis in Cancer Patients
  Oncology, 1996
• Quality of life consequences of chemotherapy-induced emesis
  Quality of Life Research, 1992